Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SANUWAVE Health, Inc. (SNWV)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.25-60.73%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
0.37 → 0.37 EPS · FY ending Dec 31, 2027 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for SNWV yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve full year 2026 revenue of about $53 million | SANUWAVE aims to grow revenue to about $53 million in 2026. | Intact | Full year 2026 revenue falls below $51 million | Revenue: $9.739M FY2026-Q2; GAAP. Published target: ~$53 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 20269,739,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth story with some recurring consumables revenue, rather than a proven durable compounder. The long-term thesis is still intact, but management execution has been volatile and the evidence snapshot gives the assessment medium confidence.
The valuation signal is mixed: SNWV is described as cheap versus peers, yet the model also shows a premium versus peers. The expectations gap is negative, and the priced-in assessment says weak execution is recognized, but not a broader stack of expensive valuation and turbulence.
Near-term results face pressure: Q2 revenue fell 3% year over year, missing the company’s growth goal, and management withdrew 2026 revenue guidance amid market and CMS reimbursement uncertainty. Consumables remain a relative strength, with Ultramist applicator and consumable revenue up 13% in Q2 and unit volumes at records, but an elevated risk of another earnings miss remains.
The multi-year thesis hinges on whether management can restore clear guidance and improve system sales while keeping consumables growth intact. Near-term signals include the next earnings update, CMS reimbursement clarity, jobs data, and results from healthcare bellwethers such as ABT, MDT, and SYK.
Over the next 1 to 3 years, SNWV’s case rests on converting consumables momentum into steadier overall execution; guidance uncertainty and repeated earnings misses leave meaningful risk. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in SANUWAVE Health, Inc.'s published investment case. The stated target is No major leadership disruptions. |
| Intact |
| Major management changes or instability continue |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Deliver Q2 2026 revenue growth of 10-15% to about $9 million | SANUWAVE aims to grow revenue to about $53 million in 2026. | Broken | Q2 2026 revenue growth falls below 10% | Revenue: $9.739M FY2026-Q2; GAAP. Published target: $8.5-$9.5 million. The target does not explicitly identify fiscal versus calendar quarters. Aug 6, 20269,739,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Resolve historical state sales and use tax liability | A supporting condition in SANUWAVE Health, Inc.'s published investment case. The stated target is Historical tax liability resolved. | Intact | Tax liability remains unresolved after one year | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.37 → $0.37 · observed estimates
$0.06B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-25 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-26 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-27 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-28 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-29 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-30 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-07-31 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-01 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-02 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-03 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-04 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-05 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-06 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-08 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-09 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-10 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-12 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-13 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-14 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-15 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-16 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-17 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-18 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-19 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-20 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-21 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-22 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-23 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-24 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-25 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-26 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-27 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-28 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-29 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-30 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-08-31 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-01 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-02 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-03 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-04 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-05 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-06 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-07 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-08 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-09 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-10 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-11 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-12 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-13 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-14 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-15 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-16 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-17 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-18 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-19 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-20 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-21 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-22 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-23 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-24 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-25 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-26 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-27 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-28 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-29 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-09-30 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-01 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-02 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-03 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-04 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-05 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-06 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-07 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-08 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-09 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-10 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-11 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-12 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-13 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-14 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-15 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-16 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-17 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-18 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-19 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-20 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-21 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-22 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-23 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-24 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-25 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-26 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-27 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-28 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-29 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-30 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-10-31 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-11-01 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-11-02 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-11-03 | $0.37 | $64,500,000 | 1 / 1 |
| 2026-11-04 | $0.37 | $64,500,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.